Request for Quotation
  • Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathwa

    /PD-ligand 1 (PD-L1) pathway can delay tumor growth and prolong the survival of tumor-bearing mice. The extracellular immunoglobulin (Ig) V domain of PD-1 is important for the

    GET PRICE BY E-MAIL

  • 3 class="res-title">PD-L1 regulates the development, maintenance, and function o

    PD-L1 regulates the development, maintenance, and function of

    loss of PD-1 enhances the responses of naive self-reactive CD8 T cells upon encounter with DCs bearing self-antigen (Probst et al., 2005; Keir et al., 2007b). In addition, PD-L1 h

    GET PRICE BY E-MAIL

  • the level of PD-1/PD-L1 in mice bearing Lewis lung carcinoma]. - P

    and its effect on the expression of programmed death 1 and programmed death ligand 1 (PD-1/PD-L1). Methods The model of lung cancer subcutaneous allograft was establishe

    GET PRICE BY E-MAIL

  • PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.

    -TPD-L1 -

    20151028-(PD-L1; also known as B7-H1) checkpoint blockade2, 3, 4 and adoptive T-cell transfusion5 in tumour-bearing mice. Moreover, tumour EZH2 and blocking studies in NSG mice bearing tumors with constitutive PD-L1 expression (CHO-hPD-L1) and in controls (CHO). Specificity of [(64)Cu]atezolizumab was further confirm

    GET PRICE BY E-MAIL

  • of EGFR Signaling to Regulate PD-L1 Expression on NSCLC c

    While a group of oncogenic mutations have been known to correlate to PD-L1 expressio have been developed for treating cancer cells bearing exon 19 deletions or L858R point

    GET PRICE BY E-MAIL

  • 3 class="res-title">Interactions between PD-1 and PD-L1 promote tolerance by blocking

    9 - :20111

    Interactions between PD-1 and PD-L1 promote tolerance by blocking

    9 - :20111112 bearing dendritic cells (DCs) pancreaticlymp nodes. Inibition cellantigen receptor (TCR)-driven stop signals depended continuedinteractions between PD-1 itsligand, PD-L1, antib

    GET PRICE BY E-MAIL

  • 3 class="res-title">NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-s

    NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-sma

    within the PD-L1high category ( 5% positive tumors), the sole parameter that affected prognosis was the expression of NCR1. However, in patients bearing tumors with negative P

    GET PRICE BY E-MAIL

  • Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1

    PD-L1/VISTA and IRAK4 programs resulted in an aggregate one-time payment of $6 million by Curis to Aurigene in exchange for an exclusive, royalty-bearing license to develop,

    GET PRICE BY E-MAIL

  • PD-1/PD-L1 expression in human T-cell leukemia virus type

    PD-ligand 1. The skin eruptions are categorized into six types: patch, plaque, multipapular, nodulotumoral, erythrodermic and purpuric. The overall survival of the eruption-bearing

    GET PRICE BY E-MAIL

  • TCD8+TPD-

    bearing recipients. PD-L1 blockade in allogeneic transplant recipients largely restored the GVL efficacy without triggering GVHD, whereas no significant antileukemia effects of P

    GET PRICE BY E-MAIL

  • TCD8+TPD-

    bearing recipients. PD-L1 blockade in allogeneic transplant recipients largely restored the GVL efficacy without triggering GVHD, whereas no significant antileukemia effects of P

    GET PRICE BY E-MAIL

  • IL-6 and PD-L1 antibody blockade combination therapy reduce

    which was localised to stroma of tumours. Combined IL-6 and PD-L1 blockade elicited efficacy in mice bearing subcutaneous MT5 (p 0.02) and Panc02 tumours (p=0.046), which

    GET PRICE BY E-MAIL

  • Blocking Programmed Death-1 Ligand-PD-1 Interactions by Loca

    PD-L1 and PD-L2 genes were expressed in tumor and vicinal muscle tissues of tumor-bearing mice and the expression level was significantly increased if a higher dosage of pSL

    GET PRICE BY E-MAIL

  • Acid-Activatable Versatile Micelleplexes for PD-L1 Blockad

    photodynamic immunotherapy with the POP PD-L1 micelleplexes, and H&E examination of the major organs at the end of antitumor study of the B16-F10 tumor-bearing C57BL

    GET PRICE BY E-MAIL

  • PD-1 antibody:PD-1

    PD-L1, Maintainsperipheral tolerance, protecting tissues from autoimmune damage Ma bearing mice Tumor injected I.V. mCT-011(BAT) administered I.V. 10ug/mouseonce da

    GET PRICE BY E-MAIL

  • regulate adaptive immunity via the PD-L1/PD-1 signalling pathw

    PD-L1+ neutrophils and PD-1+ T cells in hepatoma-bearing mice. Functionally, the PD-L1+ neutrophils from patients with HCC effectively suppressed the proliferation and activat

    GET PRICE BY E-MAIL

  • PD-L1/CD274 Antibody 17952-1-AP Proteinte

    PD-L1 (programmed cell death ligand 1, also known as CD274 or B7-H1) is the first me Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 M

    GET PRICE BY E-MAIL

  • PD1, PD-L1, Recombinant Antibodies, Immuno Check Poin

    ABEOMICS develops PD1, PD-L1, Recombinant Antibodies, Immuno Check Point Rea bearing on their surface 'non-self' antigens, usually peptides or proteins resulting from in

    GET PRICE BY E-MAIL

  • Interactions between PD1 and PDL1 promote tolerance by blockin

    bearing dendritic cells (DCs) in pancreatic lymph nodes. Inhibition of T cell antigen recep .Finally, as describes above, the disruption of PD-1 PDL-1 interactions enhances the s

    GET PRICE BY E-MAIL

  • COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tum

    PD-L1-expressing cells were immunosuppressive and were capable of eliminating CD8 T cells in vitro. Tumor-infiltrating PD-L1(+) cells isolated from tumor-bearing mice also exe

    GET PRICE BY E-MAIL

  • carcinoma-associated fibroblasts synergizes with anti-PD-L1 i

    bearing mice had cancer cell-specific CD8(+) T cells, the mice, like human patients with and α-programmed cell death 1 ligand 1 (α-PD-L1). Immune control of PDA growth wa

    GET PRICE BY E-MAIL